Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 1

Conditions

Myelodysplastic Syndromes 111Leukemia, Myeloid, Acute 106Leukemia 67Leukemia, Myelomonocytic, Chronic 35Leukemia, Myelogenous, Chronic, BCR-ABL Positive 35Myeloproliferative Disorders 30Anemia, Refractory, with Excess of Blasts 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 28Blast Crisis 24Leukemia, Myeloid, Chronic-Phase 21Congenital Abnormalities 20Myelodysplastic-Myeloproliferative Diseases 15Lymphoma 14Leukemia, Myeloid, Accelerated Phase 14Lymphoma, Non-Hodgkin 13Leukemia, Biphenotypic, Acute 13Leukemia, Monocytic, Acute 12Leukemia, Myelomonocytic, Acute 11Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 11Leukemia, Megakaryoblastic, Acute 11Leukemia, Erythroblastic, Acute 11Hodgkin Disease 11Recurrence 8Primary Myelofibrosis 8Multiple Myeloma 8Leukemia, Lymphocytic, Chronic, B-Cell 8Burkitt Lymphoma 8Lymphoma, Mantle-Cell 7Lymphoma, Large-Cell, Immunoblastic 7Lymphoma, Large B-Cell, Diffuse 7

Interventions

Cyclophosphamide 10fludarabine 8Mycophenolic Acid 7Tacrolimus 6Melphalan 6ruxolitinib 5fludarabine phosphate 5Imatinib Mesylate 5Busulfan 5Bone Marrow Transplantation 5ponatinib 4Mesna 4Azacitidine 4nilotinib 3Whole-Body Irradiation 3Thiotepa 3Stem Cell Transplantation 3Granulocyte Colony-Stimulating Factor 3Cyclosporine 311-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3lintuzumab 2Vorinostat 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 2Methotrexate 2Filgrastim 2Alemtuzumab 24-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide 2vosaroxin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Diseases × Cytarabine × Myeloid × Clear all
NCT00594555 2008-10-31

A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid Leukemia

University of Cincinnati

Phase 2 Withdrawn
20 enrolled
MyeloidOther hematologic neoplasm

Blast Crisis, Hematologic Diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡